SummaryRMgm-5238
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene mutation |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 37306042 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | RMgm-5237 |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Braumann F, Frischknecht F |
Name Group/Department | Integrative Parasitology, Center for Infectious Diseases |
Name Institute | Heidelberg University Medical School |
City | Heidelberg |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5238 |
Principal name | See below |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Sporozoites egressed efficiently from oocysts and could be isolated from the hemolymph. Western blotting of hemolymph-derived sporozoites showed similar expression of TRAP in the wild type, control and conformationally stabilized parasite lines. Immunofluorescence analysis of hemolymph derived sporozoites that were fixed but not permeabilized revealed similar signals of TRAP on the surface in all lines (Figure 2C). The numbers of sporozoites were similar in the midgut and hemolymph for all lines but showed a dramatic drop in salivary gland residency of the lines expressing TRAP in the closed and open conformations. |
Liver stage | To investigate the capacity to infect mice, we isolated sporozoites of all three lines as well as the wild type from the hemolymph and injected 10,000 sporozoites of each line into individual naïve C57Bl/6 mice. This showed the expected 100% infection rate in wild-type and S210C control parasites with a prepatent period of around 5 days. However, hemolymph sporozoites expressing the closed or open TRAP I domains infected only around 50% of mice and those infected showed a prolonged prepatent period of 6-7 days. Infection of mice by mosquito bite showed the following: the two control lines (wild type and S210C) infected all mice and showed prepatent periods of 3-4 days. In contrast, mosquitoes that were infected by the closed mutant (S210C/F224C) could not infect mice while one out of ten mice bitten by mosquitoes harboring the open mutant (S210C/Q216C) was infected. The number of salivary gland-derived sporozoites in the open mutant (S210C/Q216C) was higher, but not significantly higher, than in the closed mutant (S210C/F224C); however, we never managed to isolate sufficient numbers of sporozoites from salivary glands of the closed mutant (S210C/F224C) to conduct further experiments. |
Additional remarks phenotype | Mutant/mutation Generation of S210C, S210c/Q216C and S210C/F224C parasites Additional information |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1349800 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1335900 | ||||||||||||||||||||||||||
Gene product | thrombospondin-related anonymous protein | sporozoite surface protein 2 | ||||||||||||||||||||||||||
Gene product: Alternative name | sporozoite surface protein 2; SSP2; SSP-2; TRAP | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Short description of the mutation | P. berghei trap replaced with different mutated forms of trap (point mutations) | ||||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||||
Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | No selectable marker | ||||||||||||||||||||||||||
Promoter of the selectable marker | No | ||||||||||||||||||||||||||
Selection (positive) procedure | No | ||||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||||
Additional remarks genetic modification | Generation of S210C, S210c/Q216C and S210C/F224C parasites To generate the parasite lines S210C, S210C/Q216C and S210C/F224C we made use of a synthetic trap gene that had been codon modified for E. coli K12 and used previously to create I domain exchange mutants (Klug et al., 2020). The synthetic trap gene cloned in the pMK-RQ vector (Invitrogen) was targeted by site-directed mutagenesis using the primers P1149/P1150 (S210C), P1153/P1154 (Q216C) and P1151/P1152 (F224C). S210C/Q216C and S210C/F224C mutations were introduced sequentially. Mutated sequences were cloned into the Pb238-TRAP-NdeI/PacI vector (NdeI/PacI), linearized (ScaI-HF) and transfected into P. berghei ANKA using standard protocols (Janse et al., 2006). Isogenic parasite populations were generated as described previously (Klug et al., 2020). | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |